subtype had a lower risk score than the other pathological subtypes. To identify the underlying biological characteristics of the constructed immune low-risk score group (Fig. 5B ). The GSEA results showed that allograft rejection, IL-6/JAK/STAT3 signalling, the inflammatory response, interferon-α response, interferon-γ response and TNF-α signalling via the NFκB pathway were the 2 5 6 predominant upregulated pathways in the low-risk score group. In contrast, the E2F identify the underlying biological characteristics in the immune signature, WGCNA 2 6 0 was performed, and the correlation of risk score and immune infiltration status with 2 6 1 module membership was analysed. The soft threshold selection is shown in Fig. S8 .
6 2
The module-trait heatmap illustrates that the brown module had a significant p value 2 6 3 with both immune signature and immune infiltration status (Fig. 5E) ; the coefficients 2 6 4
were -0.64 and 0.8, respectively. The association between module membership and from the brown module with a coefficient greater than 0.5 were selected as hub genes,
and GO enrichment analysis revealed that T cell activation and lymphocyte activation 2 6 8
were the most significantly enriched biological processes, which further confirmed
the results from the DEG analysis. The spectrum of somatic mutations in patients with IDCs is known to be varied.
7 2
We next investigated the distributions of somatic mutations and observed different patterns among IDCs in terms of total mutation burden (TMB). The risk score from
the immune signature had a positive correlation with TMB in IDC patients (Fig. 6A ).
7 5
By applying a random forest algorithm, we identified 35 highly variable mutated genes that were associated with the immune signature (Fig. 6B) . TP53 was the 2 7 7
predominant gene of the 35 identified genes.
7 8
Construction of a nomogram to predict overall survival in IDC patients
We constructed a nomogram that integrated clinicopathological features with the 2 8 0 immune signature to predict the survival probability of IDC patients (Fig. 7A) the follow-up period (Fig. 7B ).
8 6
The immune signature predicted the immunotherapeutic benefits in IDC patients
VEGF-A, the main mediator in tumour angiogenesis, hinders T cell infiltration in tumour microenvironment but not in the low immune infiltration tumour 2 9 3 microenvironment ( Fig. 8A and 8B ). Furthermore, perforin, the molecular effector
found in the granules of cytotoxic T lymphocytes and natural killer cells, also showed 2 9 5 a negative correlation with VEGF-A expression (Fig. 8C) . Finally, the positive
correlation of VEGF-A and the risk score was identified. PD-1, PDL-1 and cytotoxic
T lymphocyte antigen-4 (CTLA-4) are promising targets for the treatment of patients with breast and non-small cell lung cancer. PD-1, PDL-1, and CTLA-4 antibodies are undergoing studies for the treatment of breast cancer. We analysed the correlation of for IDCs with high immune infiltration status. In our constructed immune signature, antibodies in patients with low risk score. Lastly, we checked the correlation of the GSE20685 cohorts (Fig. S8 ). In this study, we depicted the immune landscape of IDC using a large cohort. The immune landscape might explain the differences in prognoses of patients with IDC and CTLA-4 expression was found to be highly associated with the risk score. The patients with low risk scores had increased expression levels of PD-1, PDL-1, and
CTLA-4, indicating a potentially high response rate to PD-1, PDL-1, and CTLA-4
antibodies.
In our analysis, the IDCs were clustered into three main clusters (low immune patients in the high-infiltration cluster had the best survival probability compared with infiltration score, interferon-γ signature, and cytotoxic activity score may lead to an From the immune landscape in IDCs, we built an immune signature that included FLT3LG is a crucial cytokine that controls the development of DCs and is particularly antitumour effect in IDC patients with low risk scores. Furthermore, the GSEA results
revealed high levels of IFN-γ, TNF-α, and TNF-α secretion in the low-risk group,
which contribute to the antitumour activity in IDC patients with low risk scores. analysis revealed that T cell activation was the most significantly enriched biological
process, indicating that the T cell-mediated immune response is the central event in
both immune infiltration and the immune signature.
The spectrum of somatic mutations varied in IDC patients. The different mutation common gene mutations in IDCs (44% and 33%, respectively). In the 35 gene
variables, GATA3, a key regulator of ER activity, is a newly identified gene that is
mutated in IDCs (5% in ILC versus 13% in IDC, q = 0.03) (3). Mutations in GATA3
are more frequent in luminal A IDC and are mutually exclusive with FOXA1 events.
The differential expression level and enrichment for mutations of GATA3 in IDCs and CTLA-4 treatment. Similarly, the immune signature we constructed also indicated that
high expression levels of PD1, PDL-1, and CTLA-4 correlated with low risk score.
Therefore, patients with a low risk score could derive more benefit from 4 2 9
immunotherapy than patients with a high risk score.
In the current study, we performed a comprehensive evaluation of the immune landscape. This analysis of TME immune infiltration patterns has shed light on how Availability of data and materials
The datasets supporting the conclusions of this article are available in the Xena The authors declare that they have no competing interests. Z. analysed the data. XW. B., and YF. W. wrote the paper. YB. Z., K. Z., and R. S. We would like to thank Dr Michael Rosemann for helpful discussions and Hierarchical clustering was performed with Euclidean distance and Ward linkage. Three distinct immune infiltration clusters, here termed high infiltration, median
infiltration, and low infiltration, were defined. B, Interaction of the TME immune cell types. The size of each term represents the survival impact of each TME cell type, calculated by log 10 (log-rank test P value). The connection of TME immune cells recurrence-free survival. groups.
0 6
A, The distribution of risk scores in low, mediate and high immune infiltration Relative interferon-γ signature in the low-and high-risk score groups. F, Comparison CYT: cytotoxic activity scores. infiltration ssGSEA score. The correlation between module membership and gene significance in the brown ontology; GSEA: gene set enrichment analysis. invasive ductal carcinoma; OS: overall survival; and RFS: recurrence-free survival. The AUC(t) of the multivariable models indicated that the nomogram had the highest predictive power for overall survival. PRF1 expression in high and low immune infiltration conditions. P, The correlation of
CTLA-4 expression with the immune signature. and the OS probability of IDC patients. immune signature and the OS probability of IDC patients. signature and the RFS probability of IDC patients. and GSE86948 (B). probability of IDC patients in the high-and low-risk score groups.
A, The ssGSEA scores were higher in the high-and low-risk score groups. B, The and the OS probability of IDC patients in the high-risk score group. from the comparison between the ssGSEA score from the low-and high-risk score
group. E, The distribution of immune infiltration patterns in different pathological distribution of risk scores at different pathological stages. 
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